Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Option and Sells Shares

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 6, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,901 shares of common stock at a price of $12.28 per share.
• Simultaneously, Campbell sold 7,901 shares of common stock at a weighted average price of $12.5048, with prices ranging from $12.50 to $12.57.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
• Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and holds options for 67,100 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports routine stock transactions by the CEO under a pre-existing trading plan. There's no indication of unusual activity or cause for alarm, but also no specific positive news.

Positives

• The CEO's transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially creating short-term price volatility.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Investors often monitor these transactions for insights into management's perspective on the company's prospects. Rule 10b5-1 plans are frequently used to schedule these transactions in advance, mitigating concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock transactions in a transparent and compliant manner.
• Comparing Campbell's stock ownership and option holdings to those of CEOs at similar-sized biotech companies (e.g., BioMarin, Sarepta Therapeutics) could provide context on the magnitude of his stake.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates